Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studiesAlzheimer's && Dementia :: Diagnosis, Assessment && Disease Monitoring.  11:180-190. 2019
2019 Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.Neurobiology of Disease.  124:152-162. 2019
2019 Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.Nature Genetics.  51:414-430. 2019
2019 Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics.Scientific Reports.  9:2235. 2019
2019 Nicastrin haploinsufficiency alters expression of type I interferon-stimulated genes: the relationship to familial hidradenitis suppurativaClinical and Experimental Dermatology2019
2018 Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia statesScientific Reports.  8. 2018
2018 Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s diseaseScientific Reports.  8. 2018
2018 Sex-specific genetic predictors of Alzheimer's disease biomarkers.Acta Neuropathologica.  136:857-872. 2018
2018 Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.Nature Communications.  9:4273. 2018
2018 Medical decision-making in progressive supranuclear palsy: A comparison to other neurodegenerative disorders.Parkinsonism and Related Disorders2018
2018 Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.JAMA Neurology.  75:989-998. 2018
2018 Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.Molecular Neurodegeneration.  13:32. 2018
2018 Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.Journal of Neuroscience.  38:2341-2358. 2018
2018 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.Anesthesiology.  128:728-744. 2018
2018 Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s DementiaMolecular Neurobiology2018
2018 Shared Functions of Perirhinal and Parahippocampal Cortices: Implications for Cognitive Aging.Trends in Neurosciences.  41:349-359. 2018
2017 Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer's Disease via Fusion of Clinical, Imaging and Omic FeaturesScientific Reports.  7. 2017
2017 Genetic influences on cognition in progressive supranuclear palsy.Movement Disorders.  32:1764-1771. 2017
2017 Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex PenaltyScientific Reports.  7. 2017
2017 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.Annals of Neurology.  82:622-634. 2017
2017 Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.Nature Genetics.  49:1373-1384. 2017
2017 Transethnic genome-wide scan identifies novel Alzheimer's disease loci.Alzheimer's and Dementia.  13:727-738. 2017
2017 Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects.Journal of Neural Transmission.  124:721-738. 2017
2017 Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.JAMA Neurology.  74:557-566. 2017
2017 Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia.Brain.  140:1447-1465. 2017
2017 Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer's disease.Scientific Reports.  7:39880. 2017
2017 Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease.Neurobiology of Aging.  49:216.e7-216.e13. 2017
2016 Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.Movement Disorders.  31:1574-1577. 2016
2016 Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.Parkinsonism and Related Disorders.  28:29-35. 2016
2016 Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.Parkinsonism and Related Disorders.  28:41-48. 2016
2016 Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test.Genes, Brain and Behavior.  15:588-603. 2016
2016 Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.Nature Communications.  7:11934. 2016
2016 Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.JAMA Neurology.  73:721-732. 2016
2016 Assessment of the genetic variance of late-onset Alzheimer's disease.Neurobiology of Aging.  41:200.e13-200.e20. 2016
2016 Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.Movement Disorders.  31:742-747. 2016
2016 A novel Alzheimer disease locus located near the gene encoding tau protein.Molecular Psychiatry.  21:108-117. 2016
2016 Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci.PLoS ONE.  11:e0148717. 2016
2016 Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.Annals of Neurology.  80:858-870. 2016
2015 Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses.Alzheimer's and Dementia.  11:1439-1451. 2015
2015 The Alzheimer's disease risk factor CD2AP maintains blood-brain barrier integrity.Human Molecular Genetics.  24:6667-6674. 2015
2015 Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.Brain.  138:3716-3733. 2015
2015 Association of long runs of homozygosity with Alzheimer disease among African American individualsJAMA Neurology.  72:1313-1323. 2015
2015 Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study.PLoS Medicine.  12:e1001841. 2015
2015 Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE.Nature Communications.  6:6760. 2015
2015 Effects of Exercise on Progranulin Levels and Gliosis in Progranulin-Insufficient Mice.eNeuro.  2. 2015
2015 Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.Journal of Neuroscience.  35:6221-6230. 2015
2015 Rarity of the Alzheimer disease-protective APP A673T variant in the United States.JAMA Neurology.  72:209-216. 2015
2015 Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.Blood.  125:591-599. 2015
2015 Noradrenergic dysfunction in Alzheimer's disease.Frontiers in Neuroscience.  9:220. 2015
2014 Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia.Journal of Neuroscience.  34:16482-16495. 2014
2014 AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.Journal of Biomolecular Screening.  19:1338-1349. 2014
2014 Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.JAMA Neurology.  71:1394-1404. 2014
2014 Seizure resistance without parkinsonism in aged mice after tau reduction.Neurobiology of Aging.  35:2617-2624. 2014
2014 Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD.Journal of Experimental Medicine.  211:1937-1945. 2014
2014 Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.Lancet Neurology.  13:676-685. 2014
2014 The dendritic hypothesis for Alzheimer's disease pathophysiology.Brain Research Bulletin.  103:18-28. 2014
2014 ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.Journal of Clinical Investigation.  124:981-999. 2014
2013 Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice.Journal of Neuroscience.  33:5352-5361. 2013
2013 Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease.Journal of Cell Science.  126:1278-1286. 2013
2013 Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.Alzheimer's and Dementia.  9:176-188. 2013
2013 The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).Alzheimer's and Dementia.  9:189-198. 2013
2012 Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis.Nature Genetics.  44:1349-1354. 2012
2012 Mouse models of frontotemporal dementia.Annals of Neurology.  72:837-849. 2012
2012 Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases.Human Molecular Genetics.  21:3500-3512. 2012
2012 Mouse models of Alzheimer's disease.Brain Research Bulletin.  88:3-12. 2012
2012 Challenges and opportunities for characterizing cognitive aging across species.Frontiers in Aging Neuroscience.  4:6. 2012
2012 Usp14 deficiency increases tau phosphorylation without altering tau degradation or causing tau-dependent deficits.PLoS ONE.  7:e47884. 2012
2011 Geriatric epilepsy: research and clinical directions for the future.Epilepsy and Behavior.  22:103-111. 2011
2011 Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.Nature Genetics.  43:436-441. 2011
2011 Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.Journal of Neuroscience.  31:700-711. 2011
2011 Contemporary approaches to Alzheimer's disease and frontotemporal dementiaMethods in Molecular Biology.  670:1-9. 2011
2011 Contemporary approaches to Alzheimer's disease and frontotemporal dementia.Methods in Molecular Biology.  670:1-9. 2011
2011 Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: Depletion of calcium-dependent proteins and inhibitory hippocampal remodelingMethods in Molecular Biology.  670:245-262. 2011
2011 Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling.Methods in Molecular Biology.  670:245-262. 2011
2011 Step-by-step in situ hybridization method for localizing gene expression changes in the brainMethods in Molecular Biology.  670:207-230. 2011
2011 Step-by-step in situ hybridization method for localizing gene expression changes in the brain.Methods in Molecular Biology.  670:207-230. 2011
2009 Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.Journal of Neuroscience.  29:9104-9114. 2009
2008 Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.Journal of Neuroscience.  28:5007-5017. 2008
2008 Abnormal social behaviors in mice lacking Fgf17.Genes, Brain and Behavior.  7:344-354. 2008
2007 Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.Neuron.  55:697-711. 2007
2007 Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.Science.  316:750-754. 2007
2006 100 years and counting: prospects for defeating Alzheimer's disease.Science.  314:781-784. 2006
2006 Frontotemporal dementia.Current Neurology and Neuroscience Reports.  6:481-489. 2006
2006 Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.Neuron.  51:703-714. 2006
2005 Frontotemporal dementia progresses to death faster than Alzheimer disease.Neurology.  65:719-725. 2005
2005 Frontotemporal lobar degeneration: demographic characteristics of 353 patients.Archives of Neurology -Chigago-.  62:925-930. 2005
2003 Polyneuropathy following gastric bypass surgery.American Journal of Medicine.  115:679-680. 2003
2001 Memory-forming chemical reactions.Reviews in the Neurosciences.  12:41-50. 2001
2000 MAPK regulation of gene expression in the central nervous system.Acta Neurobiologiae Experimentalis.  60:377-394. 2000
1999 A biochemical blueprint for long-term memory.Learning and Memory.  6:381-388. 1999
1999 The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus.Journal of Neuroscience.  19:4337-4348. 1999
1998 Protected-site phosphorylation of protein kinase C in hippocampal long-term potentiation.Journal of Neurochemistry.  71:1075-1085. 1998
1998 Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation.Journal of Neuroscience.  18:5508-5516. 1998
1998 A role for superoxide in protein kinase C activation and induction of long-term potentiation.Journal of Biological Chemistry.  273:4516-4522. 1998
1996 Transient activation of cyclic AMP-dependent protein kinase during hippocampal long-term potentiation.Journal of Biological Chemistry.  271:30436-30441. 1996
1996 A biochemist's view of long-term potentiation.Learning and Memory.  3:1-24. 1996
1995 Regulation of adenylyl cyclase in LTPBehavioral and Brain Sciences.  18:485-486. 1995
1992 Ca(2+)-induced persistent protein kinase C activation in rat hippocampal homogenates.Journal of receptor research.  14:109-126. 1992
1988 Identification of an insulin-like factor in astrocyte conditioned medium.Brain Research.  460:60-67. 1988

Chapter

Year Title Altmetric
2016 Animal models of dementia.  77-93. 2016
2016 Frontotemporal Dementia.  141-175. 2016
2011 Preface 2011
2009 Animal models of dementia.  131-141. 2009

Principal Investigator On

  • BIN1, Interneuron Activity, and Network Dysfunction in Alzheimer Disease  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by BIOGEN IDEC, INC. 2017 - 2021
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University in St. Louis 2013 - 2020
  • Therapeutic Strategies in Mouse Models of FTD Due to Progranulin Insufficiency  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2017 - 2019
  • Private Grant  awarded by C2N DIAGNOSTICS, LLC 2015 - 2019
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin Mutations  awarded by National Institute on Aging/NIH/DHHS 2017 - 2019
  • Causes, Treatment, and Prevention of Corticobasal Degeneration  awarded by University of California, San Francisco 2014 - 2018
  • Private Grant  awarded by AVID RADIOPHARMACEUTICALS 2014 - 2018
  • Developing Inhibitors Of Tau-SH3 Interactions As Treatments For Alzheimer's Disease And Hyperexcitability  awarded by WESTON BRAIN INSTITUTE 2017 - 2018
  • Private Grant  awarded by ALECTOR, INC. 2016 - 2018
  • Development of Inhibitors of the Tau-Fyn Interaction For the Treatment of Alzheimer's Disease  awarded by BRIGHT FOCUS FOUNDATION 2015 - 2018
  • Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study  awarded by American College of Radiology 2016 - 2018
  • Therapeutic Strategies in Mouse Models of FTD Due to Progranulin Insufficiency (Consortium for Frontotemporal Dementia Research)  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2017
  • Consortium for Frontotemporal Dementia Research  awarded by University of California, San Francisco 2008 - 2017
  • BIN1 and Tau Interactions Regulating Neuronal Calcium  awarded by Alzheimer's Association 2014 - 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • Investigating the Impact of Cognition on Functional Ability in PSP  awarded by CUREPSP 2015 - 2017
  • Mechanisms for the Benefit of Tau Reduction in Alzheimer Disease Models  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2017
  • Targeting the Tau-Fyn Interaction in Alzheimer's Disease  awarded by WESTON BRAIN INSTITUTE 2016 - 2017
  • Mechanisms of Frontotemporal Dementia Like Behavior in Progranulin Deficient Mice  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2016
  • Weston Advisor Fellowship  awarded by WESTON BRAIN INSTITUTE 2015 - 2016
  • Tau and Glutamatergic Synapses in Frontotemporal Dementia  awarded by National Institute on Aging/NIH/DHHS 2013 - 2016
  • Molecular Mechanisms of Aging-Related Neuronal Dysfunction in Progranulin-Insufficient Mice  awarded by American Federation for Aging Research 2014 - 2015
  • Epileptiform Activity in Neurodegenerative Disease  awarded by STEPHEN BECHTEL JR. FUND 2009 - 2014
  • Characterizing an Inducible Model for the Protective Effects of Tau Reduction  awarded by American Health Assistance Foundation 2010 - 2013
  • Private Grant  awarded by ALLON THERAPEUTICS 2010 - 2013
  • Tau and Fyn in Alzheimer's Disease Pathogenesis  awarded by ALZHEIMER'S OF CENTRAL ALABAMA 2012
  • The Role of Tau in Neurodegeneration  awarded by STEPHEN BECHTEL JR. FUND 2009 - 2012
  • Mechanisms for Tau Involvement in Alzheimer's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2008 - 2012
  • Investigator On

  • Identifying Therapeutic Targets That Confer Synaptic Resilience to Alzheimer's Disease  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • Circadian Dysfunction and Neurodegenerative Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2023
  • Private Grant  awarded by Genentech 2018 - 2022
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2022
  • UAB Training Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2018 - 2022
  • Targeting Rho Kinases for Alzheimer's Disease Therapeutics  awarded by National Institute on Aging/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2017 - 2022
  • Private Grant  awarded by NEURIM PHARMACEUTICALS 2017 - 2021
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by AVANIR PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2015 - 2019
  • Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People with Alzheimer Dementia and Traumatic Brain Injury  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2019
  • Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin Mutations  awarded by National Institute on Aging/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by EISAI, INC. 2013 - 2019
  • Reducing Tau as a Therapeutic Strategy for Improving Cognitive Dysfunction in Parkinson's Disease  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2019
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2019
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California 2016 - 2018
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2018
  • Private Grant  awarded by ASSUREX HEALTH INC. 2016 - 2018
  • Circadian Dysfunction and GSK3 in Neurodegenerative Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2018
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2017 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Functional Change in Mild Cognitive Impairment  awarded by National Institute on Aging/NIH/DHHS 2010 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study: A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2015 - 2016
  • Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)  awarded by University of Southern California 2015 - 2016
  • Alzehimer's Disease Neuroimaging Initiative (ADNI)  awarded by University of California, San Diego 2005 - 2016
  • Training Program in the Neurobiology of Cognition and Cognitive Disorders  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - The LEARN Study A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of California, San Diego 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Preclinical Test for the Efficacy of Adrenergic Agents in Treatment of AD  awarded by National Institute on Aging/NIH/DHHS 2012 - 2015
  • A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-To-Moderate Alzheimer's Disease  awarded by University of California, San Diego 2010 - 2014
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2009 - 2013
  • Amyloid Imaging, VMCI, and Analysis for ADNI  awarded by University of California, San Diego 2009 - 2012
  • Education And Training

  • Doctor of Medicine, Baylor College of Medicine
  • Doctor of Philosophy in Neuroscience, Baylor College of Medicine
  • Full Name

  • Erik Roberson
  • Blazerid

  • erobers